U.S. flag

An official website of the United States government

NM_016038.4(SBDS):c.183_184delinsCT (p.Lys62Ter) AND Inborn genetic diseases

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Mar 21, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000622680.12

Allele description [Variation Report for NM_016038.4(SBDS):c.183_184delinsCT (p.Lys62Ter)]

NM_016038.4(SBDS):c.183_184delinsCT (p.Lys62Ter)

Gene:
SBDS:SBDS ribosome maturation factor [Gene - OMIM - HGNC]
Variant type:
Indel
Cytogenetic location:
7q11.21
Genomic location:
Preferred name:
NM_016038.4(SBDS):c.183_184delinsCT (p.Lys62Ter)
HGVS:
  • NC_000007.14:g.66994286_66994287delinsAG
  • NG_033069.1:g.2482_2483delinsAG
  • NM_016038.4:c.183_184delinsCTMANE SELECT
  • NP_057122.2:p.Lys62Ter
  • NP_057122.2:p.Lys62Ter
  • LRG_104t1:c.183_184delTAinsCT
  • LRG_104:g.6315_6316delinsCT
  • LRG_104p1:p.Lys62Ter
  • NC_000007.13:g.66459273_66459274delinsAG
  • NM_016038.2:c.183_184delTAinsCT
  • NM_016038.3:c.183_184delinsCT
  • NM_016038.4:c.183_184delTAinsCTMANE SELECT
  • p.Lys62*
  • p.Lys62X
Protein change:
K62*; LYS62TER
Links:
OMIM: 607444.0001; dbSNP: rs113993991
NCBI 1000 Genomes Browser:
rs113993991
Molecular consequence:
  • NM_016038.4:c.183_184delinsCT - nonsense - [Sequence Ontology: SO:0001587]
Functional consequence:
effect on RNA splicing [Variation Ontology: 0362]

Condition(s)

Name:
Inborn genetic diseases
Identifiers:
MeSH: D030342; MedGen: C0950123

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000740931Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(Mar 21, 2023)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Mutations in SBDS are associated with Shwachman-Diamond syndrome.

Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, Rommens JM.

Nat Genet. 2003 Jan;33(1):97-101. Epub 2002 Dec 23.

PubMed [citation]
PMID:
12496757

Structural and mutational analysis of the SBDS protein family. Insight into the leukemia-associated Shwachman-Diamond Syndrome.

Shammas C, Menne TF, Hilcenko C, Michell SR, Goyenechea B, Boocock GR, Durie PR, Rommens JM, Warren AJ.

J Biol Chem. 2005 May 13;280(19):19221-9. Epub 2005 Feb 8.

PubMed [citation]
PMID:
15701631
See all PubMed Citations (4)

Details of each submission

From Ambry Genetics, SCV000740931.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

The c.183_184delTAinsCT (p.K62*) alteration, located in exon 2 (coding exon 2) of the SBDS gene, consists of an in-frame deletion of TA and insertion of CT at nucleotide positions 183 to 184. This changes the amino acid at position 62 from a lysine (K) to a stop codon. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This mutation was reported in 82 of 250 disease alleles in a cohort of individuals with Shwachman-Diamond syndrome. In eight of the families studied, this mutation was found as part of a complex allele, c.[183_184delTAinsCT;258+2T>C], in trans with an isolated copy of c.258+2T>C (Boocock, 2003). In another study, this alteration was described compound heterozygous with c.258+2T>C in five individuals who presented with pancreatic insufficiency and failure to thrive; three of those individuals also had persistent neutropenia (Kawakami, 2005). A functional study in yeast cells found that this mutation resulted in complete loss of function (Shammas, 2005). Based on the available evidence, this alteration is classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 30, 2024